Market growth influenced due to following factors-
- Rising incidence of neurological diseases.
- Increasing investments in neuroscience research.
- Growth in the pharmaceutical and biotechnology industries.
Global market size-
According to research report the Neuroscience Antibodies Market is expected to reach $4.18 Billion by 2023, at a CAGR of 10.2%.
The neuroscience antibodies market is fragmented, with the presence of several large as well as emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the neuroscience antibodies market. Other major players include BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), GenScript (CHINA), Rockland Immunochemicals (US), Santa Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).
Top Market Segments-
Based on technology, the neuroscience antibodies market is segmented into immunoassays/immunochemistry, molecular diagnostics, clinical chemistry, and other technologies. In 2018, immunoassays/immunochemistry segment is expected to account for the largest share of the neuroscience antibodies and assays market.
Based on application, the neuroscience antibodies and assays market is segmented into research, drug discovery and development, and in vitro diagnostics. The in vitro diagnostics applications segment is expected to register the highest CAGR during the forecast period.
For Details, Download PDF Brochure Here
Geographic Overview -
In 2018, North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to the increasing investments for the development of structure-based drug designs, growing research in the field of genomics and proteomics, rising demand for high-quality research tools for data reproducibility, and the focus of stakeholders on research projects involving proteins, associated biomolecules, and genes.